Navigating the Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma

被引：24

作者：

Nastoupil, Loretta J. ^{[1
,3
]}

Bartlett, Nancy L. ^{[2
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[2] Washington Univ, Siteman Canc Ctr, St Louis, MO USA

[3] Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Blvd,Unit 429, Houston, TX 77030 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 04期

关键词：

RITUXIMAB PLUS CYCLOPHOSPHAMIDE; PREVIOUSLY UNTREATED PATIENTS; SOUTHWEST-ONCOLOGY-GROUP; NON-HODGKIN-LYMPHOMA; DOUBLE-HIT LYMPHOMA; SINGLE-ARM; OPEN-LABEL; ELDERLY-PATIENTS; PHASE-III; R-CHOP;

D O I：

10.1200/JCO.22.01848

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Diffuse large B-cell lymphoma, the most common subtype of non-Hodgkin lymphoma, comprises a heterogenous group of morphologically, genetically, and clinically distinct diseases. Several recent advances have affected the treatment landscape, which had been mostly stagnant for the past few decades. We will review the practice-changing studies in frontline (POLARIX), early relapse (ZUMA-7 and TRANSFORM), and multiple recurrent (ZUMA-1, JULIET, TRANSCEND, L-MIND, and LOTIS-2) stages and discuss how the treatment landscape may evolve with the emergence of bispecific antibodies.

引用

页码：903 / +

页数：12

共 50 条

[21] Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab
Papageorgiou, Sotirios G.
Thomopoulos, Thomas P.
Liaskas, Athanasios
Vassilakopoulos, Theodoros P.
CANCERS, 2022, 14 (08)
[22] Upfront therapy for diffuse large B-cell lymphoma: looking beyond R-CHOP
Hill, Brian T.
Kahl, Brad
EXPERT REVIEW OF HEMATOLOGY, 2022, 15 (09) : 805 - 812
[23] Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment
Liu, Yang
Barta, Stefan Klaus
AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (05) : 604 - 616
[24] Treatment of diffuse large B-cell lymphoma
Gleissner, B.
Zwick, C.
Pfreundschuh, M.
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2008, 133 (36) : 1785 - 1794
[25] Diffuse Large B-Cell Lymphoma's New Genomics: The Bridge and the Chasm
Crombie, Jennifer L.
Armand, Philippe
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (30) : 3565 - +
[26] Evolving insights into the genomic complexity and immune landscape of diffuse large B-cell lymphoma: opportunities for novel biomarkers
El Hussein, Siba
Shaw, Kenna R. M.
Vega, Francisco
MODERN PATHOLOGY, 2020, 33 (12) : 2422 - 2436
[27] Real-world data for lenalidomide maintenance in responding patients of diffuse large B-cell lymphoma
Wang, Xiaoyan
Yu, Lu
Jiang, Xinlu
Ding, Kaiyang
CANCER MEDICINE, 2023, 12 (09): : 10553 - 10562
[28] NOVEL THERAPIES IN THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA
Carlo-Stella, C.
Calabretta, E.
HAEMATOLOGICA, 2021, 106 (10) : 201 - 202
[29] Current Frontline Treatment of Diffuse Large B-Cell Lymphoma
Spinner, Michael A.
Advani, Ranjana H.
ONCOLOGY-NEW YORK, 2022, 36 (01): : 51 - 58
[30] Cost burden of diffuse large B-cell lymphoma
Harkins, R. Andrew
Patel, Sharvil P.
Flowers, Christopher R.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2019, 19 (06) : 645 - 661

← 1 2 3 4 5 →